Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal

Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.

Incyte looks to address coming patent cliff by buying Escient

Incyte Corporation sees potential in Escient Pharmaceuticals Inc.’s MRGPR X2 and X4 antagonists to augment ongoing programs in its pipeline and to begin generating revenue at about the same time that the biotech’s top-seller, Jakafi (ruxolitinib), is slated to lose US patent protection. That was a driving factor behind the Delaware-based firm’s decision to pay $750m for privately held Escient, which brings a pair of Phase II assets to Incyte’s existing inflammation and immune disease pipeline.

More from Deals

Sumitomo Offloads Asia Pharma Ops To Marubeni For $480m

 
• By 

The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.

Asia Deal Watch: Dr. Reddy’s Gets Regional Rights To Pair Of Bio-Thera Biosimilars

 

Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.

Novo Adds Lexicon’s Novel Obesity Drug To Deal Flurry

 

The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.

Deal Watch: Eyenovia Looks At New Direction In Proposed Merger With Betaliq

 
• By 

Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.

More from Business

Cerevance To Focus On Parkinson’s Adjunctive Therapy After Phase II Miss

 
• By 

After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.

Baxdrostat, AstraZeneca’s Next Big CVRM Bet

 
• By 

The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.

Stock Watch: How Tariff Threat Might Boost Pharma Q1

 
• By 

Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.